Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Enhanced Recovery After Surgery in Surgical Specialties: Gynecologic Oncology 2018
2018 Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy 2018
2018 The impact of racial, geographic, and socioeconomic risk factors on the development of advanced-stage cervical cancer 2018
2018 Predictors of Unplanned Reoperation for Ovarian Cancer Patients from the National Surgical Quality Improvement Program Database 2018
2018 The challenge of HPV vaccination uptake and opportunities for solutions: Lessons learned from Alabama 2018
2018 Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer. 2018
2018 High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women with Low-Grade Cervical Cytology 2018
2018 Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212 Pb-TCMC-Trastuzumab 2018
2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma 2018
2018 Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466 2018
2018 A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer 2018
2017 The evolution of and evidence for opportunistic salpingectomy 2017
2017 The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis 2017
2017 Preventing human papillomavirus–related cancers: we are all in this together 2017
2017 Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review 2017
2017 Does obesity affect pathologic agreement of initial and final tumor grade of disease in endometrial cancer patients? 2017
2017 Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth 2017
2016 Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service 2016
2016 Ovarian cancer and the immune system — The role of targeted therapies 2016
2016 Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma 2016
2016 Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974 2016
2016 Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes? 2016
2016 Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancer 2016
2015 PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis 2015
2015 Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project 2015
2015 A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer 2015
2015 Niclosamide analogs for treatment of ovarian cancer 2015
2015 Ovarian and cervical cancer patient derived xenografts: The past, present, and future 2015
2014 Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? 2014
2014 Outcomes of gynecologic oncology patients undergoing gastrografin small bowel follow-through studies. 2014
2014 Validation of a venous thromboembolism risk assessment model in gynecologic oncology. 2014
2014 Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study. 2014
2014 Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients 2014
2014 Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancer 2014
2014 Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab 2014
2014 Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer 2014
2014 Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96 2014
2014 Outcomes of gynecologic oncology patients undergoing robotic-assisted laparoscopic procedures in a university setting 2014
2014 Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center 2014
2013 The Wnt/β-catenin pathway in ovarian cancer: A review 2013
2013 Screening behaviors and cultural barriers in women with newly diagnosed cervical cancer. 2013
2013 Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis 2013
2013 Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma 2013
2013 Perioperative morbidity and mortality in octogenarians with ovarian cancer 2013
2013 Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials 2013
2013 Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women 2013
2012 A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer 2012
2012 The utilization of palliative care in gynecologic oncology patients near the end of life. 2012
2012 Management of complex pelvic masses using a multivariate index assay: A decision analysis 2012
2012 Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy 2012
2012 The core competencies of James Marion Sims, MD. 2012
2012 Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion 2012
2012 The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells 2012
2012 The use of retinoids in ovarian cancer: A review of the literature 2012
2011 Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies 2011
2011 A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma 2011
2011 Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer 2011
2011 Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy: does preoperative anticoagulation matter? 2011
2011 The efficacy and toxicity of bevacizumab in combination with gemcitabine in patients with recurrent ovarian cancer 2011
2011 Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model 2011
2010 Robotic surgery in gynecologic oncology fellowship programs in the USA: A survey of fellows and fellowship directors 2010
2010 Overcoming TRAIL resistance in ovarian carcinoma 2010
2010 Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies 2010
2010 The clinical impact of computed tomography immediately following primary chemotherapy in patients with epithelial ovarian cancer 2010
2009 Life-space assessment in urogynecology and gynecological oncology surgery patients: A measure of perioperative mobility and function 2009
2009 The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. 2009
2009 The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer 2009
2009 Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model 2009
2009 Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: Implications for adjuvant therapy 2009
2009 The management of cervical intraepithelial neoplasia during pregnancy: Is colposcopy necessary? 2009
2009 Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer 2009
2009 In vitro chemoresponse assay results and population chemotherapy response rates in endometrial cancer. 2009
2009 The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. 2009
2009 The effect of obesity on survival in patients with ovarian cancer 2009
2009 The role of comprehensive surgical staging in patients with endometrial cancer. 2009
2008 Conservative Management of Postoperative Fever in Gynecologic Patients Undergoing Major Abdominal or Vaginal Operations 2008
2008 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects 2008
2008 Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. 2008
2008 Lynch syndrome in women less than 50 years of age with endometrial cancer 2008
2008 Lipoxygenase pathway receptor expression in ovarian cancer 2008
2008 Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model 2008
2007 Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma [15] 2007
2007 Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: A retrospective university experience 2007
2007 Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis. 2007
2007 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers 2007
2007 Complete uterine necrosis following chemoradiation for advanced cervical cancer: a case report. 2007
2007 Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: A multiinstitutional experience 2007
2007 Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model 2007
2007 A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer 2007
2007 Diagnostic loop electrosurgical excisional procedure for discrepancy: Do preoperative factors predict presence of significant cervical intraepithelial neoplasia? 2007
2007 A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer [14] 2007
2006 A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer 2006
2006 Cervical intraepithelial neoplasia in adolescent women: Incidence and treatment outcomes 2006
2006 Fertility sparing therapy in a patient with placental site trophoblastic tumor: A case report 2006
2006 Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision 2006
2006 Bowel Resection at the Time of Primary Debulking for Epithelial Ovarian Carcinoma: Outcomes in Patients Treated with Platinum and Taxane-Based Chemotherapy 2006
2006 Unilateral cervical cancer in a patient with cervix duplex 2006
2006 Outcomes of gynecologic oncology patients admitted to the intensive care unit following surgery: A university teaching hospital experience. 2006
2006 Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer 2006
2006 Recurrent basosquamous cell carcinoma of the vulva 2006
2006 Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis 2006
2006 Use of complementary and alternative medicine and spiritual practices among women with ovarian carcinoma in the southeastern United States. 2006
2006 Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model 2006
2006 Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients 2006
2006 Use of a fascial prosthesis for management of abdominal compartment syndrome secondary to obstetric hemorrhage. 2006
2006 Re: "outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy" [2] (multiple letters) 2006
2005 The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: A patient care evaluation study from the American College of Surgeons National Cancer Data Base 2005
2005 A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses 2005
2005 Predictors of outcomes for women with cervical carcinoma 2005
2005 Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies. 2005
2005 Management strategies for abnormal early pregnancy: A cost-effectiveness analysis 2005
2005 Feasibility of hand-assisted laparoscopic surgery (HALS) in gynecologic oncology patients. 2005
2005 A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia 2005
2005 A prospective evaluation of "see and treat" in women with HSIL Pap smear results: Is this an appropriate strategy? 2005
2005 Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis 2005
2005 Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy 2005
2005 Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy 2005
2004 Early abdominal incision recurrence in a patient with stage i adenocarcinoma of the endometrium 2004
2004 Some remarks on the somatic expression of sperm protein 17 [1] (multiple letters) 2004
2004 A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia 2004
2004 The impact of aborted radical hysterectomy in patients with cervical carcinoma 2004
2004 Feasibility study of liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked stage IIIC/IV ovarian cancer patients. 2004
2004 Poor prognosis of taxane/platinum treated advanced stage ovarian cancer patients despite a negative second look laparotomy. 2004
2004 Expression of sperm protein 17 (Sp17) in ovarian cancer 2004
2004 Immunohistochemical Evaluation of the c-kit Proto-oncogene in Sarcomas of the Uterus: A Case Series 2004
2004 The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy 2004
2003 A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3 2003
2003 Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigation 2003
2003 Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids 2003
2003 Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy 2003
2003 Complications of indwelling venous access devices in patients with gynecologic malignancies 2003
2003 Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy 2003
2002 Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture 2002
2002 Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture. 2002
2002 Uterine leiomyosarcoma metastatic to the thyroid 2002
2002 Uterine leiomyosarcoma metastatic to the thyroid. 2002
2002 A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis 2002
2002 Conservative management of Stage I endometrial carcinoma after surgical staging 2002
2001 Endometrial carcinoma. 2001
2001 Predictors of outcome in small cell carcinoma of the cervix - A case series 2001
2000 A patient presenting with a pelvic mass, elevated CA-125, and fever 2000

Research Overview

  • Cost-effectiveness Analyses
    Surgical Outcomes
    Management of Endometrial Cancer
    Targeted Therapies
    Quality Improvement
    Robotic Surgery
    Enhanced Recovery after Surgery
  • Principal Investigator On

    Investigator On

  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2018 - 2023
  • Private Grant  awarded by GENMAB 2018 - 2023
  • UAB 1753 A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer  awarded by University of Chicago 2018 - 2023
  • Private Grant  awarded by Leap Therapeutics, Inc. 2017 - 2022
  • Private Grant  awarded by Genentech 2017 - 2022
  • Private Grant  awarded by IMMUNOGEN, INC. 2017 - 2022
  • Private Grant  awarded by MATEON THERAPEUTICS, INC. 2016 - 2021
  • Private Grant  awarded by PLEXXIKON 2016 - 2021
  • Private Grant  awarded by ABBVIE INC 2015 - 2020
  • Improving Surgical Outcomes and Experience with Patient-Centered Technology  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2018 - 2020
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by LICOR, INC. 2017 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2014 - 2018
  • Using the Genomic Profile of High Intermediate Risk Endometrial Cancer Patients to Differentiate Patients at High Risk of Recurrence from the Majority with Low Risk of Recurrence  awarded by FOUNDATION FOR GYNECOLOGIC ONCOLOGY 2016 - 2017
  • Private Grant  awarded by AMGEN, INC. 2012 - 2016
  • Gynecologic Oncology Group Clinical Trials  awarded by GYNECOLOGIC ONCOLOGY GROUP 2012 - 2016
  • Private Grant  awarded by ASTRAZENECA AB 2014 - 2015
  • Private Grant  awarded by Genentech 2011 - 2013
  • Education And Training

  • UAB Hospital, Internship 1967
  • UAB Hospital, Residency 2000
  • UAB Hospital, Residency 1972
  • UAB Hospital, Postdoctoral Fellowship 2003
  • Full Name

  • John Straughn